[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334973-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334973-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","emerging-innate-immune-cells-in-cancer-immunotherapy-promises-and-challenges","Emerging Innate Immune Cells in Cancer Immunotherapy: Promises and Challenges","","Immune checkpoint inhibitor (ICI) therapy improves survival for some cancer patients, yet many do not benefit. Building on insights into how immune effector cells interact with tumors, cell-based approaches are emerging for patients less responsive to ICI treatment. Early progress with chimeric antigen receptor T (CAR-T) therapy in hematologic cancers has accelerated development across innate and T-cell strategies. This review highlights current development of NK cells, γδ T cells, and macrophages, addressing key challenges and future perspectives to overcome them.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/emerging-innate-immune-cells-in-cancer-immunotherapy-promises-and-challenges/334973/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/emerging-innate-immune-cells-in-cancer-immunotherapy-promises-and-challenges/334973.png","ImageObject",300,407,{"name":42,"@type":43},"Maeve","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why do only some cancer patients benefit from immune checkpoint inhibitor (ICI) therapy?","Question",{"text":63,"@type":64},"ICI therapy has shown major survival benefits, but only a subset of patients gains clinical advantage when considering all cancer types.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What distinguishes innate immune responses from adaptive immune responses in cancer therapy?",{"text":68,"@type":64},"Innate immune responses are faster, do not require prior sensitization for activation, and can recognize targets through direct ligand-receptor interactions or pattern recognition.",{"name":70,"@type":61,"acceptedAnswer":71},"Which innate immune cell types does the review focus on for emerging cancer immunotherapies?",{"text":72,"@type":64},"The review focuses on emerging NK cells, γδ T cells, and macrophages, outlining their development and potential challenges.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334973,1790147725,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":117,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":104,"preview_page_count":4},5909877438554,"https://ap-avatar.wpscdn.com/avatar/5600025385ad2bf12a7?_k=1778553567797529272","Author Manuscript Author Manuscript Author Manuscript Author Manuscript  \n\n| | HHS Public Access\u003Cbr>Author manuscript\u003Cbr>BioDrugs. Author manuscript; available in PMC 2024 July 15. |\n| --- | --- |\n\nPublished in final edited form as:  \nBioDrugs. 2024 July ; 38(4): 499–509. doi:10.1007/s40259-024-00657-2 .  \nEmerging Innate Immune Cells in Cancer Immunotherapy: Promises and Challenges  \nJennifer Wu 1,2,3  \n1 Department of Urology, Feinberg School of Medicine, Robert Lurie Comprehensive Cancer Center, Northwestern University, 303 E. Superior St, Chicago, IL 60611, USA  \n2 Department of Microbiology and Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA  \n3 Robert Lurie Comprehensive Cancer Center, Chicago, IL, USA  \nAbstract  \nImmune checkpoint inhibitor (ICI)-based therapy has made an unprecedented impact on survival benefit for a subset of cancer patients; however, only a subset of cancer patients is benefiting from ICI therapy if all cancer types are considered. With the advanced understanding of interactions of immune effector cell types and tumors, cell-based therapies are emerging as alternatives to patients who could not benefit from ICI therapy. Pioneering work ofchimeric antigen receptor T (CAR-T) therapy for hematological malignancies has brought encouragement to a broad range of development for cellular-based cancer immunotherapy, both innate immune cell-based therapies and T-cell-based therapies. Innate immune cells are important cell types due to their rapid response, versatile function, superior safety profiles being demonstrated in early clinical development, and being able to utilize multiple allogeneic cell sources. Efforts on engineering innate immune cells and exploring their therapeutic potential are rapidly emerging. Some of the therapies, such as CD19 CAR natural killer (CAR-NK) cell-based therapy, have demonstrated comparable early efficacy with CD19 CAR-T cells. These studies underscore the significance of developing innate immune cells for cancer therapy. In this review, we focus on the current development of emerging NK cells, γδ T cells, and macrophages. We also present our views on potential challenges and perspectives to overcome these challenges.  \nOpen Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by-nc/4.0/](http://creativecommons.org/licenses/by-nc/4.0/) .  \nJennifer Wu, [jennifer.wu@northwestern.edu](jennifer.wu@northwestern.edu).  \nAuthor's Contributions Jennifer Wu formulated the concept, wrote the manuscript, and prepared all the table illustrations in this manuscript.  \nAvailability of Data and Material, Code Availability No datasets were generated and/or analyzed during the current study. Conflicts of Interest Jennifer Wu declares that she has no conflicts of interest that might be relevant to the contents ofthis manuscript.  \nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript  \nWu Page 2  \n1 Introduction  \nDifferent from adaptive immune responses, innate immune responses are faster responses. Innate immune cells recognize target cells typically through direct ligand-receptor interactions or through pattern recognition. The activa","cbCaitcriHXUgLxw","https://ap.wps.com/l/cbCaitcriHXUgLxw","pdf",375064,"English","# Abstract\n# Introduction\n# Natural Killer Cell-Based Therapy\n## Innate immune response characteristics\n## NK receptor activation and inhibitory balance\n## KIR-MHC I pathway and transplant settings","[{\"question\":\"Why do only some cancer patients benefit from immune checkpoint inhibitor (ICI) therapy?\",\"answer\":\"ICI therapy has shown major survival benefits, but only a subset of patients gains clinical advantage when considering all cancer types.\"},{\"question\":\"What distinguishes innate immune responses from adaptive immune responses in cancer therapy?\",\"answer\":\"Innate immune responses are faster, do not require prior sensitization for activation, and can recognize targets through direct ligand-receptor interactions or pattern recognition.\"},{\"question\":\"Which innate immune cell types does the review focus on for emerging cancer immunotherapies?\",\"answer\":\"The review focuses on emerging NK cells, γδ T cells, and macrophages, outlining their development and potential challenges.\"}]","Emerging Innate Immune Cells in Cancer Immunotherapy: Promises and Challenges | PDF",1790009068]